Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT06124482
Recruiting Not applicable

Performance and Safety Evaluation of the FHK®-CK Knee Prosthesis

NCT06124482 · tracked via the Priya Life Science France tracker
Sponsor
Phase
Not applicable
Started
2024-02-01
Last updated
2025-06-19

Condition(s) studied

Total Knee Arthroplasty

Investigational drug(s) / intervention(s)

Total Knee arthroplasty

Total Knee arthroplasty: The FHK-CK prosthesis (non CE-Marked, class III) is to be implanted with the use of FHK-CK instruments. The surgery has to be performed in accordance with the practice/guidelines, FHK-CK Instruction For Use (IFU) and surgical techniques documents.

Study summary

The life expectancy worldwide is increasing and leading to an increase of knee arthroplasty. Also, as millions of people around the world are currently living with a Total Knee Arthroplasty (TKA), the need for revision surgery represents a large public health burden. In this context, FH ORTHO company develops FHK®-CK (prosthesis + ancillary equipment) which is a knee prosthesis for complex first intention and revision knee arthroplasty. This new medical device complements the FHK® standard first-line range (CE marked).

The FHK®-CK ancillary equipment were designed by expert knee surgeons and is simple, reliable and reproducible. It allows for maximum versatility while remaining compact.

By completing the FHK® range of first intention prostheses, the FHK®-CK allows the surgeon to be on the same level as the competitors by having a first intention and semi-constrained prosthesis. This prosthetic arsenal allows the surgeon to opt for the best solution for his patient so that he can regain mobility and a satisfactory quality of life. Also, in case of failure of the FHK® first-line prosthesis, it will provide the surgeon and the patient with a simple alternative to prosthesis replacement. As it has been developed in line with the first intention, inter-compatibility between the two systems is possible, which simplifies the surgical procedure and reduces the risks for the patient.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patient requiring knee arthroplasty for primary or secondary gonarthrosis: \* For primary intention arthroplasty: Patient with either * major axial deviation, * major peripheral failure or * bone defect; \* For prosthesis revision surgery: Patient who have had a failed 1st implantation, with or without bone defects. * Patient able to understand and answer the questionnaires provided by the protocol; * Subject affiliated to a health insurance system or is a beneficiary; * Signed informed consent form (ICF) for participation to the research. Exclusion Criteria: * Patient with an ongoing acute infection, outside knee to be operated; * Patient with a mental or neuromuscular disorder that would create an unacceptable risk of prosthetic instability, prosthetic fixation failure or post-operative complications; * Patient with a known allergy to any of the components of the FHK®-CK implants (Nickel, Cobalt, Chromium); * Patient with a dependency (drug, alcohol,…) that could affect his/ her ability to comply with the protocol, at the investigator's discretion; * Patient requiring knee reconstruction; * Patient with any medically significant findings or significant history that may impact the safety, interpretation of results, and/ or participation of the subject in the clinical trial, as determined by the investigator; * Patient with an existing knee or hip prosthesis (outside knee to be operated) that may impact the evaluation of the FHK®-CK prosthesis; * Patient concurrently participating in another clinical trial or who has recently participated in another clinical trial for which the exclusion period has not been completed. * Vulnerable subjects : * Pregnant, parturient, or breastfeeding women, * Subject deprived of liberty, hospitalized without consent or admitted to a health or social establishment for purposes other than that of research, * Minor, * Adult under protective supervision (tutorship, curatorship), * Subject not able to understand the subject information leaflet (e.g. for linguistic or psychiatric reasons) and/or to give informed consent

Primary outcome measure(s)

Trial sites (7)

FacilityCityRegionStatus
Hôpital Privé La Châtaigneraie Beaumont France Terminated
CHRU de la Cavale Blanche Brest France Recruiting
Hôpital Beaujon AP-HP Clichy France Recruiting
Hôpital Raymond Poincaré AP-HP Garches France Recruiting
CH d'Haguenau Haguenau France Recruiting
Centre Hospitalier Régional Universitaire de Nancy Nancy France Recruiting
Groupe Hospitalier Pitié Salpêtrière AP-HP Paris France Recruiting

More FH ORTHO trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06124482 on ClinicalTrials.gov ↗ ← All trials in France